Company |
Product |
Description |
Indication |
Status |
Genentech, of South San Francisco, a unit of the Roche Group |
Tecentriq (atezolizumab) |
Monoclonal antibody targeting PD-L1 |
First-line extensive-stage small-cell lung cancer |
FDA accepted the supplemental BLA and granted a priority review; decision expected by March 18, 2019 |
Innovent Biologics Inc., of Suzhou, China |
IBI-101 |
Anti-OX40 monoclonal antibody |
Advanced solid tumors |
FDA approved IND |
Intrabio Inc., of Oxford, U.K. |
IB-1000s |
Modified amino-acid analogues/esters |
Spinocerebellar ataxias |
European Commission granted orphan medicinal drug designation |
Recordati SpA, of Milan |
REC-0559 |
Low-molecular-weight non-peptidic nerve growth factor mimetic |
Neurotrophic keratitis |
FDA granted orphan drug designation |
Notes For more information about individual companies and/or products, see Cortellis. |